ISRCTN66441193暂停未知
Improving Transplant Opportunities for Patients who are Sensitised (ITOPS): a feasibility, randomised, controlled phase III trial
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18 – 65 years
- •2. Able to give informed consent and willing to fulfil trial requirements
- •3. Completed the necessary assessments to receive a renal transplant
- •4. In stable health, as determined by the Investigator based on medical history and laboratory tests during the screening period
- •5. Negative serological test for hepatitis B (surface antigen and core antibody) and hepatitis C within the last 6 months, and HIV within the last 12 months
- •6. Documented immune status to varicella zoster virus (VZV) (at any time)
- •7. Female participant of childbearing potential must be willing to use a highly effective method of contraception for one year following rituximab (this period will also include the recommended 3 month period for avoidance of pregnancy following bortezomib). Male participants must be willing to use a highly effective form of contraception for 3 months post last dose of bortezomib
- •8. Persistent (for at least one year) and stable (tested on at least three occasions over the preceding year) circulating HLA antibodies defined by Luminex Single Antigen Bead analysis at the time of recruitment
- •9. Recipients awaiting deceased donor transplantation must have cRF >85% and at least 3 years on the transplant waiting list
- •10. Recipients with an HLA incompatible living donor who have been considered for enrolment in the UK Living Kidney Sharing Scheme must fit either of the following:
- •10.1. cRF is >95%
- •10.2. cRF is =85% and they have received no offers after three runs in the NLDKSS
排除标准
- •1. Pregnancy, planned pregnancy during the trial period, or current breast feeding
- •2. Active viral, bacterial or fungal infection precluding immunosuppression
- •3. Active malignant disease
- •4. Listed for transplantation of any organ other than kidney alone
- •5. History of active or clinically significant respiratory, gastrointestinal (including pancreatitis), hepatic, cardiac,
- •neurological, psychiatric, musculoskeletal, genitourinary, dermatological, or other disorder that, in the Investigator’s
- •opinion, could affect the conduct of the trial
- •6. History of non-adherence, alcohol or substance abuse that, in the judgment of the Investigator, may impair or risk the subject’s full participation in the trial
- •7. Positive serological test for hepatitis B, C or HIV
- •8. Negative serological test for VZV
- •9. Previous graft loss to recurrent primary disease within 2 years of transplantation
- •10. Documented intolerance of bortezomib, rituximab or their exipients, or dexamethasone
- •11. Persistent thrombocytopaenia, platelet count <100 X 109/L for the past 3 consecutive months
- •12. Persistent neutropaenia, absolute neutrophil count < 2 X 109/L for the past 3 consecutive months
- •13. Hypogammaglobulinaemia, serum IgG less than local laboratory lower limit of normal at screening
- •14. Peripheral neuropathy of any grade (reported by symptoms or on clinical examination)
- •15. Currently involved in any other clinical trial of an IMP or have taken an IMP within 30 days prior to trial entry
研究者
相似试验
进行中（未招募）
1 期
Improving Transplant Opportunities for Patients who are Sensitised (ITOPS)EUCTR2017-002602-12-GBCardiff and Vale University Health Board38
尚未招募
Unknown
ung Transplant CalculatorCTRI/2024/06/068913Armed forcres medical college pune
招募中
不适用
Development and optimization of transplantation-related in vitro assaysorgaantransplantatieanti-donor reactivityimmune reactivityNL-OMON48819Erasmus MC, Universitair Medisch Centrum Rotterdam250
进行中（未招募）
1 期
A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I)ewly diagnosed multiple myelomaMedDRA version: 16.1Level: HLTClassification code 10028229Term: Multiple myelomasSystem Organ Class: 100000004851MedDRA version: 20.0Level: LLTClassification code 10028566Term: MyelomaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2018-003590-10-GBniversity of Leeds740
已完成
Unknown
Treatment of renal transplant recipients with low bone mineral density and vascular calcification: a prospective study of alendronate therapy.Kidney transplant recipients for secondary osteoporosis and vascular calcificationJPRN-jRCT1091220155Masanori Okamoto20